Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06605404
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-18
Brief Title:
Pan-tumor MRD Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Molecular Residual Disease in Solid Tumors A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this observational study is to collect clinical information blood and tumor tissue samples from participants diagnosed with stage I stage II or operable stage III cancer in select solid tumors The information collected will be used to develop tests to better understand cancer for example to improve cancer detection and to assess the risk of cancer coming back
Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half 55 years
Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half 55 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None